Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Margherita Maffioli, MD, Francisco Cervantes, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Enrica Morra, Domenica Caramazza, MD PhD, Barbara Mora, MD, Toni Giorgino, PhD, Francesco Passamonti, MD

Blood (2014) 124 (21): 3187.

https://doi.org/10.1182/blood.V124.21.3187.3187

Published: 2014

Journal Articles

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

Blood (2014) 124 (21): 1824.

https://doi.org/10.1182/blood.V124.21.1824.1824

Published: 2014

Journal Articles

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri, Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora, Norbert Hollaender, Cristiana Pascutto, Claire Harrison, Mario Cazzola

Blood (2014) 123 (12): 1833–1835.

https://doi.org/10.1182/blood-2013-12-544411

Published: 2014

Journal Articles

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Blood (2012) 120 (6): 1197–1201.

https://doi.org/10.1182/blood-2012-01-403279

Published: 2012

Includes: Supplemental data

Journal Articles

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Srdan Verstovsek, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, Tapan Kadia, Sherry Pierce, Elias Jabbour, Gautham Borthakur, Elisa Rumi, Ester Pungolino, Enrica Morra, Domenica Caramazza, Mario Cazzola, Francesco Passamonti

Blood (2012) 120 (6): 1202–1209.

https://doi.org/10.1182/blood-2012-02-414631

Published: 2012

Journal Articles

Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,

Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Daniel L. Van Dyke, Ph.D., Domenica Caramazza, Alessandro M. Vannucchi, MD, Enrica Morra, Mario Cazzola, Arturo Pereira, MD. PhD, Francisco Cervantes, MD, Francesco Passamonti, MD

Blood (2011) 118 (21): 3833.

https://doi.org/10.1182/blood.V118.21.3833.3833

Published: 2011

Journal Articles

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, MD, Tapan Kadia, Sherry Pierce, RN, BS, Mario Cazzola, Elisa Rumi, Enrica Morra, Ester Pungolino, Domenica Caramazza, Francesco Passamonti, MD

Blood (2011) 118 (21): 793.

https://doi.org/10.1182/blood.V118.21.793.793

Published: 2011

Journal Articles

Interim 18 f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

Domenica Caramazza, Francesco Dentali, MD, Michele Merli, Giorgia Saccullo, Alessandra Malato, Gerlando Quintini, Emilio Iannitto, Francesco Passamonti, Sergio Siragusa, MD

Blood (2011) 118 (21): 5183.

https://doi.org/10.1182/blood.V118.21.5183.5183

Published: 2011

Journal Articles

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Blood (2011) 118 (21): 1746.

https://doi.org/10.1182/blood.V118.21.1746.1746

Published: 2011

Journal Articles

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Ayalew Tefferi, MD, Naseema Gangat, MD, Rakhee Vaidya, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Daniel L. Van Dyke, Ph.D., Domenica Caramazza, Animesh Pardanani, MBBS, PhD

Blood (2011) 118 (21): 2806.

https://doi.org/10.1182/blood.V118.21.2806.2806

Published: 2011

Journal Articles

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

Ayalew Tefferi, Thitina Jimma, Naseema Gangat, Rakhee Vaidya, Kebede H. Begna, Curtis A. Hanson, Daniel L. Van Dyke, Domenica Caramazza, Animesh Pardanani

Blood (2011) 118 (17): 4595–4598.

https://doi.org/10.1182/blood-2011-08-371096

Published: 2011

Includes: Supplemental data

Journal Articles

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

Rakhee Vaidya, Domenica Caramazza, Kebede H. Begna, Naseema Gangat, Daniel L. Van Dyke, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Blood (2011) 117 (21): 5612–5615.

https://doi.org/10.1182/blood-2010-11-320002

Published: 2011

Includes: Supplemental data

Journal Articles

Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Rakhee Vaidya, Domenica Caramazza, Christy Finke, Terra Lasho, MT, (ASCP), Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 3068.

https://doi.org/10.1182/blood.V116.21.3068.3068

Published: 2010

Journal Articles

Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype

Rakhee Vaidya, Domenica Caramazza, Kebede Begna, MD, Naseema Gangat, M.D., Daniel L. Van Dyke, PhD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 3069.

https://doi.org/10.1182/blood.V116.21.3069.3069

Published: 2010

Journal Articles

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

Domenica Caramazza, Terra Lasho, MT, (ASCP), Christy Finke, Naseema Gangat, David Dingli, M.D., Ph.D., Ryan Knudson, Sergio Siragusa, MD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Rhett Ketterling, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4009.

https://doi.org/10.1182/blood.V116.21.4009.4009

Published: 2010

Journal Articles

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Naseema Gangat, MD, Domenica Caramazza, MD, Rakhee Vaidya, Geeta George, PA, Kebede Begna, MD, Susan Schwager, Daniel L. Van Dyke, PhD, Curtis Hanson, MD, Wenting Wu, PhD, Animesh Pardanani, MBBS, Phd, Francisco Cervantes, MD, Francesco Passamonti, MD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4104.

https://doi.org/10.1182/blood.V116.21.4104.4104

Published: 2010

Journal Articles

Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients

Domenica Caramazza, Kebede Begna, MD, Naseema Gangat, M.D., Rakhee Vaidya, Sergio Siragusa, MD, Daniel L. Van Dyke, PhD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4122.

https://doi.org/10.1182/blood.V116.21.4122.4122

Published: 2010

Journal Articles

Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis.

Sergio Siragusa, MD, Alessandra Malato, MD, Fabio Fulfaro, Giorgia Saccullo, Domenica Caramazza, Giusy Pizzo, Lucio lo Coco, Nicola Gebbia

Blood (2009) 114 (22): 3999.

https://doi.org/10.1182/blood.V114.22.3999.3999

Published: 2009

Journal Articles

Polycythemia Vera as a Predisposing Factor for Aortic Stenosis: Prevalence and Correlation with Blood Cells Count and Mutational Status

Ri ta Barone, Clementina Caracciolo, Rosario di Maggio, Giovanni Fazio, Luciana d’Angelo, Maria Montana, Salvatore Novo, Lucio lo Coco, Domenica Caramazza, Vincenzo Abbadessa, Sergio Siragusa, MD

Blood (2008) 112 (11): 5247.

https://doi.org/10.1182/blood.V112.11.5247.5247

Published: 2008

Journal Articles

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

Gerlando Quintini, MD, Domenica Caramazza, MD, Vincenzo Barbera, MD, Silvana Maisano, MD, Vincenzo Spadola, Ph.D, Sergio Siragusa, MD, Vincenzo Abbadessa, MD

Blood (2007) 110 (11): 4354.

https://doi.org/10.1182/blood.V110.11.4354.4354

Published: 2007

NARROW

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

Interim 18 f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients

Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis.

Polycythemia Vera as a Predisposing Factor for Aortic Stenosis: Prevalence and Correlation with Blood Cells Count and Mutational Status

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only